Healing at death’s door: one patient’s mystical experience with psilocybin

Psilocybin, the active ingredient in magic mushrooms, has a long history of ceremonial use by indigenous peoples and is now being studied in Western medicine for treating existential distress in cancer patients. Palliative care has improved management of physical symptoms, but psychospiritual suffering remains difficult to treat with conventional methods. Early research on psychedelic therapies targeted the existential suffering that often accompanies dying, offering a potential new approach to healing in the context of end-of-life care.

Study at a glance

Abstract

eath is of the most certain and undeniable truths in an existence shrouded by mysteries and unknowns, yet many don't have the opportunity for a meaningful reflection on this matter until the very end of their life.Existential suffering often awaits at death's door while effective solutions remain limited.The reality is that saving lives has been a key pillar of our medical ethos and so the concept of healing while dying may seem contradictory.Palliative care has offered a paradigm shift but despite significant advances in the field with respect to controlling physiological symptoms, the psychospiritual aspects of suffering don't respond as well to conventional treatments.Psilocybin is the active ingredient in fungal species within the genus Psilocybe, which are popularly known as magic mushrooms.They grow all around the world and their ceremonial use by the indigenous has been documented for hundreds, if not thousands of years.There has been increasing interest in the use of these substances in Western medicine.Some of the earliest research studies on psychedelic therapies were focused on existential distress in cancer patients.This psychotherapeutic approach employs the use of